Polymyositis
MONDO:0019127A rare idiopathic inflammatory myopathy characterized by symmetric proximal muscle weakness and elevated muscle enzymes.
Also known as: PM, polymyositis
102 clinical trials for this condition and its sub-types, 36 tagged with Polymyositis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Polymyositis
-
Dermatomyositis 81 trials · 100 incl. sub-types
11 sub-types
- Juvenile dermatomyositis 41 trials
- Anti-MDA5 dermatomyositis 3 trials
- Clinically amyopathic dermatomyositis 1 trial · 2 incl. sub-types Sub-types →
- Adermatopathic dermatomyositis 0 trials
- Adult dermatomyositis 0 trials
- Anti-Mi2 dermatomyositis 0 trials
- Anti-NXP2 dermatomyositis 0 trials
- Anti-SAE dermatomyositis 0 trials
- Anti-TIF1 dermatomyositis 0 trials
- Classical dermatomyositis 0 trials
- Neonatal dermatomyositis 0 trials
-
Juvenile polymyositis 3 trials
Most studied deeper sub-types
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control By invitation onlyThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…
Phase 2/3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Engineered immune cells take on lupus and scleroderma in first human test
Disease control OngoingThis early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC